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Abstract 
With  the  overwhelming  volume  of  genomic  and 
molecular information available on many databases 
nowadays, researchers need from bioinformaticians 
more  than  encouragement  to  refine  their  searches. 
We present here GeneRanker, an online system that 
allows researchers to obtain a ranked list of genes 
potentially related to a specific disease or biological 
process  by  combining  gene-disease  (or  gene-
biological process) associations with protein-protein 
interactions  extracted  from  the  literature,  using 
computational  analysis  of  the  protein  network 
topology  to  more  accurately  rank  the  predicted 
associations.    GeneRanker  was  evaluated  in  the 
context  of  brain  cancer  research,  and  is  freely 
available online at http://www.generanker.org. 
Introduction 
It  is  an  exciting  time  for  genomic  research:  the 
Human Genome Project is complete, a wide array of 
high-throughput gene expression analysis techniques 
is  now  available, and genomic data is pouring into 
public  databases.  The  challenge  now is to translate 
genomic research to improved human health.  
In  order  to  discover  potential  gene  candidates  for 
their  role  in  specific  disease-related  behavior, 
researchers often use gene lists from different sources 
(such as genes annotated for a specific function in the 
Gene  Ontology)  as  a  starting  point,  proceeding  to 
further  computational  analysis  (say  by  comparing 
against clinical datasets for differential expression of 
the  target  genes)  and  empirical  validation.  This 
process  allows  some  room  for  discovery,  as  the 
function mapping of the Gene Ontology might not be 
specific  to  the  disease  the  researcher  is  studying. 
However,  these  findings  do  not  stray  too  far  from 
established  knowledge,  creating  the  bursts  of 
popularity  observed  for  genes  that  become  widely 
studied at around the same time by many laboratories.  
On  the  other  hand,  it  is  difficult  for  researchers  to 
incorporate  little  known  molecular  associations  and 
new knowledge in their discovery process, given the 
impressive  volume  of  publications  that  need  to  be 
reviewed.  For  example,  a  search  for  a single gene, 
TNF alpha, yields 76,220 articles, with almost half of 
them published in the last 5 years. Refining the search 
to TNF alpha and inflammation reduces this number 
to 15676 articles, still too many for a researcher to 
review. Finding all the protein-protein interactions in 
which  TNF  alpha  is  involved  (in order to discover 
new  potential  targets)  becomes  an  even  more 
frustrating exercise, as there is no way to express such 
a query in PubMed, and existing curated interaction 
databases cover a very small fraction  of the existing 
relevant literature
1 (less than 5%(1)). 
It  has  become  a  self-evident  truth  that  genetic 
researchers  need  more  from  bioinformaticians  than 
encouragement to refine their searches. The volume 
of  information  requires  advanced  analysis  and 
integration techniques that need to yield trustworthy 
results  of  biological  relevance.  We  present 
GeneRanker, an online system that allows researchers 
to obtain a ranked list of genes potentially related to a 
disease  or  biological  process  which  integrates 
knowledge from the literature with graph-theoretical 
analysis of relevant protein-protein interactions. 
Background 
Data sources. GeneRanker serves as an interface to a 
method  for  predicting  gene-disease  associations  by 
combining data extracted from the literature and from 
curated sources. Its biological and mathematical basis 
were  introduced  in  (2).  GeneRanker  is  not  an 
information extraction system nor a natural language 
processing  system,  as  it  relies  on  data  stored  by 
another system from our lab, CBioC (3). The CBioC 
database  contains  over  1  million  protein-protein 
interactions as well as over 300,000 gene-disease and 
250,000  gene-biological  process  associations 
extracted from 1.6 million biomedical abstracts using 
natural language processing
2. Details on related NLP 
work  have  been  previously  reported. 
  CBioC  also 
integrates  close  to  380,000  protein-protein 
interactions from IntAct(4), MINT(5), BIND(6), and 
                                                            
1  DIP,  MINT,  and  IntAct,  the  three  largest  freely  available 
databases, cover less than 10,000 articles altogether. BIND, now 
private, included interactions from 22,000 articles at its peak. 
2 The most recent CBioC database statistics are available at 
http://www.cbioc.org 
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DIP(7).  The NLP engine behind CBioC, IntEx, has 
been rated as around 65% accurate for protein-protein 
extractions from text (8), and at 77% for gene-disease 
association  extractions.  We  sought  to  increase  the 
precision  of  the  extracted  data  through  knowledge 
integration via the ranking method presented in (2), 
briefly described next. 
Method. The knowledge integration and data analysis 
method  behind  the  GeneRanker  interface  can  be 
summarized as follows:  
1.  Given  a  target  disease  or  biological  process 
name,  obtain  a  list  of  genes  known  to  be 
involved with the target disease from the CBioC 
database. This becomes the initial set.  
2.  Extract from the CBioC database all interactions 
that involve genes in the initial set. A network 
where  each  protein  has  edges  to  others  with 
which  it  reportedly  interacts  is  built  from  this 
set.  Edges  are  weighted  with  a  “confidence 
level” that reflects the source of the interactions. 
Interactions extracted from the literature have a 
confidence of 0.65 (the reported accuracy of the 
NLP  engine  behind  CBioC)  and  those  from 
curated  sources  a  1.0.  The  proteins  in  this 
network form the extended set. 
3.  Apply  a  two-part  scoring  formula  to  each  the 
extended set to predict the proteins most likely 
related to the disease.  
The  first  part  of  the  scoring  formula  counts  the 
number of interactions of each protein in the extended 
set with proteins in the initial set, and weights it with 
the  average  confidence  of  the  interactions.  The 
second part of the score measures the importance of 
the protein in keeping its “neighborhood” connected. 
Given  that  high  degrees  of  local  network 
interconnectivity identify sets of functionally related 
proteins  (9,  10),  we  hypothesized  that  the  relative 
importance of a protein in keeping this connectivity 
could  reflect  its  biological  relevance  for  particular 
molecular  behaviors,  and  by  extension  (as  the 
network is derived from proteins that are potentially 
relevant to a specific disease), its biological relevance 
with  respect  to  the  disease.  The  two  measures  are 
then combined using their harmonic mean.  
To measure the connectivity of a protein p, we use the 
traditional clustering coefficient measure from graph 
theory: the ratio of actual edges in the neighborhood 
of p to the maximum number of edges that can exist 
in the neighborhood (11), denoted cc(p). If cc(p) is 
close to 1, the small set formed by p and its neighbors 
is  highly  connected,  and  thus,  if  p  were  to  be 
“removed” from the network (aberrantly expressed), 
there would likely be another “connection” around its 
neighbors,  and  the  network  will  remain  connected 
(and  the  local  function  preserved).  Otherwise,  its 
“absence” will likely affect the function of the cluster, 
as there are not too many alternative paths. To be able 
to  combine  it  with  the  first  part  of  the  scoring 
formula,  we  use  1-cc(p)  as  the  second  part  of  the 
score for p (to match the implication of  importance 
derived from a high/low score). 
GeneRanker Interface 
The current implementation of GeneRanker includes  
the basic information for the method to work. Options 
that  will  allow  users  to  add  weights  to  the  scoring 
process (such as adding to the score of interactions 
due to phosphorylation, or to those that involve genes 
in  a  certain  region  of  the  genome),  as  well  as 
gene/protein annotation features are in development.  
Selecting  the  disease  to  study.  GeneRanker  allows 
users to enter a search term, which can be a disease or 
biological  process  –such  as  glioblastoma  or 
apoptosis-, and then queries the CBioC database for a 
list of genes and proteins found to be associated with 
that disease or process. 
Working with the initial set of genes. The list of genes 
or proteins found to be associated with the disease or 
biological  process  is  displayed  in  full  (Figure  1). 
Depending on the term, there can be anywhere from 
20 to over 300 genes and proteins in the list. The user 
can add other genes to this initial set or remove any 
deemed to be redundant or incorrect. Once the initial 
set  is  finalized,  the  protein  network  will  be 
constructed  upon  clicking  on  the  “Expand  the 
Network” button. 
 
Figure  1.  Initial  set  of  genes.  After  the  user  types  a 
disease or biological process, the GeneRanker system web 
interface  (available  at  www.generanker.org)  displays  an 
initial  set  of  genes  obtained  from  relevant  gene-disease 
associations  extracted  by  CBioC  from  biomedical 
literature. Accuracy is estimated at 75% for this initial set. 
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Ranking the extended set of proteins. For each gene 
in the initial set, GeneRanker obtains a set of all the 
interactions in which it is involved. This is the most 
time consuming step (taking on average about 10-15 
minutes), and results in an extended set of genes that 
is  about  100  times  as  large  as  the  initial  set.  All 
interactions  among  genes  in  these  larger  set  (the 
extended set) form the network that will be analyzed 
to assign a score to each gene, as described in the 
previous  section.  The  user  can  then  choose  to 
continue  ranking  the  extended  set  or  store  the 
network (as an XML file). Figure 3 shows the final 
screen,  once  the  genes  have  been scored. The user 
initiates the scoring process by clicking on “Compute 
Seed  Measure”,  “Compute  Clustering  Coefficient” 
and “Compute Combined Score” in succession. The 
combined score is the weighted harmonic mean of the 
two scores, and the user can vary the relative weight 
of each score by changing the “Seed Measure” and 
“Clustering  Coefficient”  values.  The  process  is 
memory  intensive,  but  usually  runs  in  less  than  5 
minutes altogether. The user can sort the genes by any 
of the scores or by gene name. 
Automatic Annotation. A useful feature on this last 
screen is the “Annotate” function. Users can select a 
subset  of  genes  which  are  annotated  using 
information from PubMed. There are two annotation 
measures: “PubMed Count” and “Overrepresentation 
Index”.  “PubMed  Count”,  is  the  number  of 
publications found in PubMed when querying for the 
protein  name  and  the  disease  or  biological  process 
term  together.  The  “Overrepresentation  Index”, 
calculated as in (12), is a measure of how much more 
likely  it  is  to  find  the  protein  in 
PubMed  together  with  the  disease-
related term as compared to with other 
terms. In other words, it is a measure 
of specificity: it shows the strength of 
the relationship between a gene and a 
disease  by  indicating  how  much  the 
observed number of co-occurrences in 
the PubMed documents deviates from 
the  expected  number  if  the  co-
occurrence were by chance. Thus, an 
index greater than 1 indicates the co-
occurrence is not likely by chance, and 
the more it exceeds 1, the stronger the 
association.  For  example,  for  “tp53”, 
“PubMed Count” is 60, while “insulin” 
has  190.  However,  the  over-
representation index for tp53 is 13.49, 
while for insulin, it is 0.48, indicating 
insulin  occurs  often  with  other  terms 
as  well,  not  only  glioblastoma. 
Tempting as it might be to use the overrepresentation 
index  as  part  of  the  ranking  criteria,  it would only 
help  to  find  known  targets,  and  will  exclude 
potentially  valuable  new  discoveries  that  can  be 
unveiled through the GeneRanker method. Thus, the 
measure is included only as aggregated information 
for the researcher.  
Evaluation 
We  conducted  an  evaluation  of  the  gene  ranking 
method in the context of a specific disease (glioma), 
using  two  different  approaches:  (i)  comparing 
GeneRanker  lists  to  those  obtained  from  text 
extraction,  and  (ii)  evaluating  GeneRanker  results 
against a clinical glioma dataset. 
Comparing GeneRanker to text extraction. Given that 
biomedical  text  mining  has  reached  a  point  were 
performance improvements of even 1 to 2 percent are 
very  difficult  to  achieve  (and  highly  significant),  a 
comparison of the precision of GeneRanker to lists 
obtained  from  the  CBioC  database  provides  a 
measure of the value of post-processing results from 
text  extraction  using the knowledge integration and 
computational  analysis  techniques  in  GeneRanker. 
The value of such post-processing becomes clear if 
we  compare  the  17%  performance  gain  of 
GeneRanker over text extraction (see Table 1) to the 
1.23%  that  was  consider  a  “highly  significant 
difference”  in  the  Biocreative  II gene mention task 
(13).  An  overview  of  current  challenges  and 
limitations  of  biomedical  text  mining  and  why 
traditional  extraction  techniques  are  reaching  their 
performance limit for many tasks appears in (14).  
 
Figure  3.  GeneRanker,  showing  the  top  ranked  genes  for  glioblastoma.  The 
interface allows users to apply the method to any disease or biological process, 
obtaining a ranked list of potentially related genes. Precision reaches 91 to 94% 
for the top 100 genes in the list. 
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To  measure  the  performance  of  a  text  extraction 
system such as the one behind CBioC, one rates its 
precision (percentage of the extracted entities that are 
considered correct), and its recall (percentage of the 
available  entities  extracted).  The  two  measures  are 
often  combined  using  their  harmonic  mean,  or  f-
measure. In biological domains, and particularly for 
gene  ranking  systems,  precision  is  much  more 
relevant than recall(15), as researchers won’t usually 
mind  not  getting  everything  that  can  possibly  be 
extracted as long as what is extracted is correct. This 
view was confirmed by the cancer researchers in the 
team.  In  view  of  this,  we  designed  the  evaluation 
methodology to emphasize precision. 
In  order  to  compare  the  precision  of  the  top  200 
genes  in  the  GeneRanker  list  to  that  of  pure  text 
extraction, we extracted all gene-disease associations 
in  the CBioC database where the disease term was 
either “glioma”, “glioblastoma”, or “astrocytoma” (a 
total of 1560 entries). We then randomly selected 3 
groups of 200 genes each for annotation. Each gene 
in  these  3  lists,  plus  the  top  200  genes  from 
GeneRanker  was  automatically  annotated  with  two 
numeric  measures  obtained  from  PubMed:  one 
indicated the number of articles returned by searching 
for  the  gene  name  co-occurring  with  “glioma”, 
“glioblastoma”,  or  “astrocytoma”.  In  addition,  we 
also searched PubMed for the occurrence of the gene 
alone and the glioma-related terms alone. The number 
of publications returned was noted for each search. 
The genes were also similarly searched in OMIM. 
Based  on  whether  the  gene  was  in  OMIM,  plus 
considering  the  number  of  publications  where  the 
gene  co-occurs  with  the  disease-terms  and  the 
overrepresentation  index,  each gene was marked as 
either  a  true  positive  (TP)  or  false  positive  (FP). 
Results are summarized in Table 1. Genes that had no 
hits  in  PubMed  were  considered  a  false  positive, 
although they could in fact be related to the disease 
(these are the potential new targets).  
Evaluating against a clinical dataset. The next step 
of contextual evaluation was to test the method in a 
biological context for its ability to identify potential 
gene targets (known or not). The method was run for 
“glioblastoma”, and the final ranked list was analyzed 
by TGen’s Brain Tumor Unit researchers Armstrong 
and  McDonough.  The  top  300  genes  reported  by 
GeneRanker  to  be  related  to  glioma  were  queried 
against  a  whole-genome  expression  microarray 
(Affimetrix U133 Plus 2.0) using the Repository of 
Molecular  Brain  Neoplasia  DaTa  (REMBRANDT) 
Database(16),  seeking  to  discern  candidate  genes 
which demonstrate variations in expression related to 
this type of glioma. Similarly, 10 random gene lists 
and a list generated from Gene Ontology annotations 
for cell-cell adhesion, a biological process relevant to 
glioma. Table 2 summarizes the results.  
As shown in Table 2, the set of probes obtained from 
the  GeneRanker  list  are  2x  differentially  expressed 
28.2% of the time, which represents an 8.7% greater 
yield over the Gene Ontology list. This represents an 
effect-size statistic of 4.0. Effect size is the preferred 
method of determining both the statistical and clinical 
significance of the difference between two groups(17, 
18), and, as proposed by Cohen (19), it is estimated 
by the ratio of the mean difference between the two 
Table  1.  Results  of  comparing  GeneRanker  to  text 
extraction in finding genes associated to a specific disease. 
True positives (TP) are genes that are either associated to 
the disease in OMIM or that were found to co-occur in 
PubMed abstracts with an overrepresentation index greater 
than  1.  GeneRanker  exceeds  the  performance  of  text 
extraction by up to 17%.  
  TP  FP 
Precision 
% 
Text extraction list 1  153  47  77% 
Text extraction list 2  159  41  80% 
Text extraction list 3  150  50  75% 
Average(std dev)  154.0(4.6)  46.0(4.6)  77%(2%) 
GeneRanker (top 50)  47  3  94% 
Effect (gain in precision wrt text extraction)  17%  
GeneRanker (top 100)  91  9  91% 
Effect (gain in precision wrt text extraction)  14% 
GeneRanker (top 200)  175  25  88% 
Effect (gain in precision wrt text extraction)  11% 
     
Table 2. Evaluation against glioblastoma (GBM) dataset. 
The  percentage  of  probes  with  2-fold  differential 
expression (up or down) in the GBM dataset are noted for 
(a) a set of 10 random lists of 300 genes, (b) a list of genes 
obtained from gene ontology (GO) annotations for cell-cell 
adhesion, and (c) the top 300 genes from GeneRanker. The 
effect  size  of  the  later  with  respect  to  the  GO  list  (and 
therefore, wrt the random list) is highly significant.  
 
% of 2x diff. 
expr. probes   
Random gene list 1  16.4% 
Random gene list 2  13.6% 
Random gene list 3  17.4% 
Random gene list 4  14.5% 
Random gene list 5  14.8% 
Random gene list 6  17.9% 
Random gene list 7  11.6% 
Random gene list 8  18.8% 
Random gene list 9  16.1% 
Random gene list 10  14.8% 
Average(std dev)  15.6% (2.2%) 
GO list for cell-cell adhesion  19.5% 
Effect size (wrt random list)  1.2 
GeneRanker top 300 list  28.2% 
Effect (% difference wrt GO list)  8.7% 
Effect size   4.0 
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groups  divided  by  the  standard  deviation  of  the 
control group. In the Cohen (19) scale (adjusted for 
effect size rather than correlation, as done in (20)), 
anything  with  an  effect  size  of  over  0.8  is  large, 
between 0.5 and 0.8 is moderate, between 0.2 and 0.5 
is  small,  and  anything  smaller  than  0.2  is 
insubstantial.  Thus,  the  effect  size  shown  for  the 
GeneRanker list is highly significant. 
Conclusion 
We  have  presented  GeneRanker, an online tool for 
predicting associations between proteins and diseases 
using  data  from  the  literature.  The  precision  for 
GeneRanker was measured to be between 91% and 
94% for glioblastoma, surpassing the precision of text 
extraction  systems  alone.  It  also  outperforms  other  
gene ranking methods, such as the one by Morrison et 
al (21), which reports a maximum accuracy of less 
than 90% for their best combination of inputs; and the 
one by Seki and Mostafa (22)  to associate genes and 
hereditary  diseases,  which  reports  an  accuracy  of 
74%  for  their  best  prediction.  Our  results  are  thus 
very encouraging, although evaluation of the method 
for other diseases is still ongoing.  
Overall,  GeneRanker  was  judged  by  the  BTU 
researchers as a promising tool for finding potential 
gene targets. In contrast to a list obtained from other 
sources (such as the Gene Ontology), the GeneRanker 
top-ranked list includes well-known targets (such as 
P53, EGFR, VCAM1, AKT1, and CD44) increasing 
confidence on the tool, as well as potentially novel 
targets (at least one novel target that could have been 
missed otherwise has already been identified and is 
currently under empirical validation).  
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